Fluticasone for wheezing in infants aged 0–24 months
Part of Lungs & breathing clinical trials.
This trial tests whether a nebulized (inhaled) steroid called fluticasone propionate is safe and effective for infants 0–24 months old who are hospitalized for wheezing. It aims to reduce symptoms like wheezing and coughing.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your child is between birth and 24 months old.
- Your child is currently in the hospital with wheezing, and the wheezing started within the last 72 hours.
- Your child's wheezing symptoms have a total score of 2 or higher based on a doctor's assessment.
- Your child does not have certain heart, lung, or immune system conditions (the doctor will check).
- Your child has not received steroid medication by mouth or injection for this episode of wheezing.
- Your child has not been in another clinical trial in the last 90 days.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a short course of oral prednisolone (an anti-inflammatory steroid) helps young children under 2 who have wheezing triggered by a rhinovirus cold. It aims to see if steroid treatment can improve symptoms after an emergency visit.
This trial studies whether an early steroid treatment can lower the chance that children will go on to develop asthma after their first severe “wheezing” episode caused by a rhinovirus (a common cold virus). If you qualify, the goal is to prevent future asthma rather than just treat the current episode.
This study tests if giving oral steroids (medicine to reduce airway swelling) only when needed based on a child's own biology can help preschool children with wheezing. It aims to find the best treatment for each child, avoiding unnecessary medicine.
This study looks at young children (ages 1-5) who have had severe wheezing episodes that needed hospital care. It aims to find biomarkers (clues in the body) that could help predict which children might develop asthma later.
This study tests if the medicine Dupilumab can help control asthma and wheezing in children ages 2 to just under 6. It is for children whose symptoms are not well-managed with their current inhaler.
This Phase 3 study compares a new inhaler (QMF149: indacaterol plus mometasone) against budesonide to see which works better and is safe for children ages 6 to under 12 with asthma. You may be able to join if your child is already on a stable low-dose steroid inhaler and still has symptoms.
Hear when a new Acute Wheezing Disorders in Infants Aged 0 to 24 Months trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.